Genomics Core Leuven provides services in long-read sequencing and bioinformatics analysis, focusing on technologies for data management and analysis in the fields of healthcare and biomedical research.

Genomics Core Leuven

Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.

Azenta, Inc.

Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

James B. Powell

Laboratory Corporation of America Holdings

Lexogen develops innovative RNA analysis solutions and NGS services.

Metric
Company Name	Genomics Core Leuven	Azenta, Inc.	Laboratory Corporation of America Holdings	Lexogen
Symbol		AZTA	LH
MSH ID	BE:GENOMICSCORE	COM:AZENTA	COM:LABCORP	COM:LEXOGEN
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Medical - Instruments & Supplies	Medical - Diagnostics & Research	Biotechnology
Country	BE	US	US	AT
Stage
Employee Count		3.40K	67K
Website	genomicscore.be	azenta.com	labcorp.com	lexogen.com
LinkedIn
Founders

Metric
Market Cap	2.72B	16.89B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	665.07M	12.16B
Revenue (LTM)
Revenue (NTM)
Gross Profit	263.14M	3.15B
EBITDA	41.18M	1.70B
Operating Income	-73.13M	1.12B
Net Income	-14.26M	418M
EPS	-0.22	4.80
Diluted EPS	-0.22	4.77
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.39	0.27
Operating Profit Margin	-0.11	0.09
EBITDA Margin	0.06	0.14
Net Profit Margin	-0.02	0.04
Return on Equity	-0.01	0.06
Return on Assets	-0.01	0.03
Return on Capital Employed	-0.03	0.09

BE:GENOMICSCORE

Genomics Core Leuven

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-346.32	28.87
P/B Ratio	1.55	2.42
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.25	1.59
EV Multiple	455.78	8.77

Metric
Days Sales Outstanding	85.91	55.66
Days Payables Outstanding	32.51	25.45
Days Inventory Outstanding	118.96	19.25
Operating Cycle	217.62	84.65
Cash Conversion Cycle	183.35	52.97
Asset Turnover	0.28	0.77

Metric
Operating Cash Flow	17.49M	1.33B
Free Cash Flow	-21.95M	874.10M
Cash Flow to Debt	1.23	0.26
Operating Cash Flow/Sales	0.14	0.11
Free Cash Flow Yield	-0.01	0.05

Metric
Cash & Equivalents	310.93M	536.80M
Accounts Receivable	33.99M	-75.30M
Inventory	115.26M	474.60M
Goodwill	691.41M	6.14B
Debt to Capitalization	0.03	0.43
Debt to Assets	0.02	0.37
Current Ratio	6.73	1.36
Quick Ratio	5.26	0.82

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.01
R&D to Revenue	0.05
SG&A to Revenue